Compare Stocks: ANL, RCUS, AMLX, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$33.64 +6.4%	$26.01	$10.83 ▼ $41.14	$3.52B	-0.13	3.68 million shs	1.82 million shs
ANL Adlai Nortye	$15.93 +4.7%	$13.11	$0.88 ▼ $17.25	$979.49M	1.04	169,531 shs	175,555 shs
DYN Dyne Therapeutics	$18.52 +1.7%	$24.50	$11.92 ▼ $27.31	$3.40B	1.08	2.74 million shs	3.20 million shs
RCUS Arcus Biosciences	$24.04 -2.2%	$28.80	$11.30 ▼ $31.74	$3.13B	0.81	1.36 million shs	1.72 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+6.39%	-1.35%	+55.52%	+123.52%	+188.76%
ANL Adlai Nortye	+4.73%	+6.13%	+20.23%	+58.51%	+789.94%
DYN Dyne Therapeutics	+1.70%	-23.72%	-27.94%	+2.49%	+40.84%
RCUS Arcus Biosciences	-2.38%	-18.98%	-18.50%	+1.88%	+109.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$33.64 +6.4%	$26.01	$10.83 ▼ $41.14	$3.52B	-0.13	3.68 million shs	1.82 million shs
ANL Adlai Nortye	$15.93 +4.7%	$13.11	$0.88 ▼ $17.25	$979.49M	1.04	169,531 shs	175,555 shs
DYN Dyne Therapeutics	$18.52 +1.7%	$24.50	$11.92 ▼ $27.31	$3.40B	1.08	2.74 million shs	3.20 million shs
RCUS Arcus Biosciences	$24.04 -2.2%	$28.80	$11.30 ▼ $31.74	$3.13B	0.81	1.36 million shs	1.72 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+6.39%	-1.35%	+55.52%	+123.52%	+188.76%
ANL Adlai Nortye	+4.73%	+6.13%	+20.23%	+58.51%	+789.94%
DYN Dyne Therapeutics	+1.70%	-23.72%	-27.94%	+2.49%	+40.84%
RCUS Arcus Biosciences	-2.38%	-18.98%	-18.50%	+1.88%	+109.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$36.50	8.50% Upside
ANL Adlai Nortye	2.71	Moderate Buy	$29.50	85.19% Upside
DYN Dyne Therapeutics	2.81	Moderate Buy	$32.17	73.69% Upside
RCUS Arcus Biosciences	2.62	Moderate Buy	$38.30	59.32% Upside

Current Analyst Ratings Breakdown

Latest ANL, RCUS, AMLX, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	RCUS Arcus Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$31.00
9/9/2026	DYN Dyne Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$45.00 ➝ $36.00
9/9/2026	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $26.00
9/9/2026	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$35.00 ➝ $30.00
9/9/2026	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Underweight	$17.00 ➝ $10.00
9/8/2026	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$37.00
9/8/2026	RCUS Arcus Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $40.00
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
9/8/2026	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $57.00

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	42.90	N/A	N/A	$2.78 per share	12.10
ANL Adlai Nortye	$18.06M	56.82	N/A	N/A	($0.21) per share	-75.86
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
RCUS Arcus Biosciences	$247M	12.39	N/A	N/A	$5.84 per share	4.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest ANL, RCUS, AMLX, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
ANL Adlai Nortye	0.04	9.55	0.65
DYN Dyne Therapeutics	0.28	12.02	12.02
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
ANL Adlai Nortye	35.21%
DYN Dyne Therapeutics	96.68%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
ANL Adlai Nortye	N/A
DYN Dyne Therapeutics	9.46%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable

ANL, RCUS, AMLX, and DYN Headlines

Recent News About These Companies

Arcus Biosciences (NYSE:RCUS) Shares Down 5.6% - Here's What Happened

September 11, 2026 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

September 9, 2026 | businesswire.com

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Allianz Asset Management GmbH Purchases New Stake in Arcus Biosciences, Inc. $RCUS

September 9, 2026 | marketbeat.com

42,338 Shares in Arcus Biosciences, Inc. $RCUS Acquired by Jupiter Topco LLC

September 5, 2026 | marketbeat.com

Arcus Biosciences Advances Casdatifan With New Liver Function Study

September 4, 2026 | tipranks.com

The Manufacturers Life Insurance Company Makes New $1.41 Million Investment in Arcus Biosciences, Inc. $RCUS

September 4, 2026 | marketbeat.com

Legal & General Group Plc Invests $5.91 Million in Arcus Biosciences, Inc. $RCUS

September 4, 2026 | marketbeat.com

Corient Private Wealth LP Invests $1.82 Million in Arcus Biosciences, Inc. $RCUS

September 4, 2026 | marketbeat.com

Arcus Biosciences, Inc. $RCUS Position Decreased by Montanova Capital LLC

September 1, 2026 | marketbeat.com

Wellington Management Group LLP Sells 194,068 Shares of Arcus Biosciences, Inc. $RCUS

September 1, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $16.74 Million in Arcus Biosciences, Inc. $RCUS

September 1, 2026 | marketbeat.com

Man Group plc Acquires New Shares in Arcus Biosciences, Inc. $RCUS

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Arcus Biosciences, Inc. $RCUS

August 27, 2026 | marketbeat.com

Deutsche Bank AG Invests $2.92 Million in Arcus Biosciences, Inc. $RCUS

August 27, 2026 | marketbeat.com

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

August 26, 2026 | businesswire.com

Odyssean LLC Makes New Investment in Arcus Biosciences, Inc. $RCUS

August 26, 2026 | marketbeat.com

PDT Partners LLC Buys New Stake in Arcus Biosciences, Inc. $RCUS

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Purchases New Position in Arcus Biosciences, Inc. $RCUS

August 25, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,827 Shares

August 25, 2026 | insidertrades.com

BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANL, RCUS, AMLX, and DYN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$33.64 +2.02 (+6.39%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$33.75 +0.11 (+0.33%)

As of 04:07 AM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Adlai Nortye NASDAQ:ANL

$15.93 +0.72 (+4.73%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$15.82 -0.11 (-0.66%)

As of 04:17 AM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Dyne Therapeutics NASDAQ:DYN

$18.52 +0.31 (+1.70%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$18.53 +0.01 (+0.05%)

As of 04:06 AM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Arcus Biosciences NYSE:RCUS

$24.04 -0.55 (-2.24%)

Closing price 09/14/2026 03:59 PM Eastern

Extended Trading

$23.82 -0.21 (-0.89%)

As of 05:30 AM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, RCUS, AMLX, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, RCUS, AMLX, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, RCUS, AMLX, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, RCUS, AMLX, and DYN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Adlai Nortye NASDAQ:ANL

Dyne Therapeutics NASDAQ:DYN

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, RCUS, AMLX, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, RCUS, AMLX, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, RCUS, AMLX, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, RCUS, AMLX, and DYN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Adlai Nortye NASDAQ:ANL

Dyne Therapeutics NASDAQ:DYN

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools